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Abstract: Commonly associated with dry eye, blepharitis is the most commonly encountered 
disorder in general ophthalmologic practice. Although anti-infective and anti-inflammatory 
therapies are available, eyelid hygiene is the cornerstone of effective management. A variety 
of products have been used to assist and encourage eyelid cleansing and massage. The pres-
ent study examines the ocular and periocular tolerability and acceptability of Blephagel, a 
cosmetic, poloxamer-containing gel designed specifically for cleansing the eyelid in subjects 
with sensitive skin or eyes or contact lens users. Subjects with blepharitis and sensitive skin 
or eyes, a history of atopy, or who use contact lenses applied Blephagel twice daily at home. 
Clinical ophthalmologic examinations were conducted before and 21 days after aqueous gel 
application, and subjects completed a questionnaire on the acceptability of the preparation. 
Thirty-three predominantly female subjects entered and completed the study. A total of 36% 
of the subjects had used similar products in the past, 21% regularly. Upon questioning by the 
ophthalmologist, 85% of the subjects reported acceptability of the preparation as good to very 
good, and 73% rated the efficacy as good to very good. There were minor but statistically non-
significant changes in fluorescein tear breakup time and visual acuity before and after 21 days 
of aqueous gel application. The questionnaire results indicated that the subjects found the 
product to be effective for cleansing the eyelids of mucus and squama around eyelash roots. 
Moreover, cosmetic qualities, sensation in use, and acceptability were also appreciated. No 
subject reported any adverse event considered to be related to the aqueous gel. Although the 
safety of Blephagel has already been established in standard tests, the current results suggest 
that it is also pleasant to use and acceptable to blepharitis patients with sensitive skin as an 
aid to an eyelid hygiene regime.
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Introduction
Blepharitis is a common disorder.1 Indeed, it is the most common disorder encountered 
in general ophthalmologic practice2 and is characterized by inflammation of the eyelid 
margin; sore eyelids; irritated, burning, or gritty sensations in the eye; dry, watery, 
or irritated eyes; sensations of foreign body in the eye; or eyelids sticking together 
in the morning. It is commonly associated with dry eyes. As well as being highly 
distressing for the patients, it is a risk factor for endophthalmitis following cataract 
surgery.3,4 Blepharitis can be posterior, anterior, or mixed. Posterior blepharitis involves 
  meibomian glands and is related to meibomian gland dysfunction. Anterior blepharitis 
involves the anterior lid margin and eyelashes and is typically associated with staphy-
lococcal infection or seborrhea and, for some, infection by Demodex.5,6
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The pathophysiology of blepharitis is complex and 
involves several different interacting systems, including 
secretions of the lid margin, disorder of the tear film, and 
infection of the lid margin. The structure of the lid margin 
is crucial to the health of the eyelid; the meibomian glands 
secrete lipids, which spread themselves on the tear film to 
prevent excess tear evaporation. A reduction in the quality 
or quantity of the meibomian gland secretions can result in a 
poor-quality tear film, an increased rate of evaporation, dry 
eyes, and blepharitis. Disorders of the meibomian glands may 
be primary or secondary to skin disorders such as rosacea 
or seborrheic dermatitis. Infectious agents can interact with 
meibomian secretions and promote, propagate, and perpetu-
ate meibomian gland dysfunction, tear film instability, and 
ocular surface inflammation.7
The pathologic meibomian and sebaceous secretions in 
meibomian gland dysfunction contain irritative lipids like free 
fatty acids and fatty acid peroxides that promote inflammation 
of the lid margin and should be cleaned off the lid margin. The 
colarettes are a shelter for Demodex mites, which are very 
frequently found in eyelashes with colarettes.8 Mechanical 
removal of these crusts and collarettes is thus an important 
step of lid hygiene. Although soap and mild detergents are 
effective, they are often irritative and might have a negative 
effect on the ocular surface, especially on the tear film.
Eyelid hygiene has an important role to play in the preven-
tion and treatment of blepharitis. This includes not only cleaning 
of the eyelid but also encouraging lid warming and specific mas-
sage manoeuvers to promote meibomian gland secretion and 
the removal of crusts from the eyelashes and eyelid margin. The 
mechanism of action of such eyelid cleaning procedures and 
massage appears to be multifactorial and includes thickening 
and stabilization of the meibomian lipid layer9 (partly, at least, 
by manual stimulation and expression of the meibomian glands) 
as well as reducing bacterial colonization, which has deleterious 
effects on the meibomian lipid layer.10 A variety of products (in 
the form of shampoos and scrubs formulated specifically for 
eyelid hygiene) exist to assist in the cleaning/massage routine 
and appear to be effective,11 some commercially formulated 
cleansers being less irritating than soap or shampoo.12 Patients 
appear to favor such products over simple soap or diluted 
shampoos,13 and their use may improve compliance with eyelid 
hygiene regimes. Interestingly, studies suggest that an eyelid 
hygiene regime not only reduced preoperative conjunctival 
flora14 but also was effective in reducing the number of cataract 
surgery cancellations due to blepharitis.15
Although pharmacologic approaches, including anti-
bacterial, anti-inflammatory medication, can be useful in 
particular cases, the mainstay of treatment and prevention in 
blepharitis is rigorous eyelid hygiene. There is considerable 
scope for products that not only provide effective cleaning of 
the eyelid and lid margin but are more convenient and pleas-
ant in everyday use. Such products should be acceptable to 
blepharitis patients, who are often sensitive to the application 
of such products because of their sensitive skin and eyes. 
Indeed, compliance with eyelid hygiene may be poor in such 
patients because of intolerance to topical treatments.
Blephagel (Laboratoires Thea, Clermont-Ferrand, France) 
is a cosmetic, poloxamer-containing gel designed specifically 
for cleansing the eyelid that is currently undergoing develop-
ment as an aid to eyelid hygiene. Blephagel has a soothing 
action that encourages routine use and leaves the skin non-
greasy. Rinsing is not required, so the product may be used 
away from the bathroom or when traveling.
The safety and tolerability of Blephagel has been 
demonstrated in in vitro and in vivo studies in healthy 
volunteers.16,17
Although the in vitro and in vivo data are encouraging, to 
date there have been no studies on the tolerability and accept-
ability of Blephagel in the more sensitive environment of the 
eyelid and periocular region, nor among subjects who might 
be expected to be particularly sensitive to the application of 
the product around the eye.
The objective of the current study was to determine the 
ocular and periocular tolerability of Blephagel in subjects 
with sensitive skin or eyes, contact lens users, or those with 
a personal or family history of atopy.
Methods
This open study without comparator was undertaken at a sin-
gle center in France. Although the investigational product is 
classified as a cosmetic, the study was conducted in the spirit 
of the most recent recommendations of the World   Medical 
Association (Declaration of Helsinki 1964; last amend-
ment in force), Good Clinical Practice, and International 
  Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (Topic E6: 
CPMP/ICH/135/95), and in accordance with relevant French 
legislation and the standard operating procedure of Institut 
d’Expertise Clinique, Lyon, France, insofar as these were 
applicable to the type of product.
investigational product
Blephagel is a colorless, aqueous gel comprising carbomer, 
poloxamer 188, macrogol 4000, sodium hydroxy methyl 
glycinate, sodium hydroxyde 1 N, and purified water, 
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  presented in an airless plastic pump flask for administration 
by the subject. The product was applied twice daily for 3 
weeks.
Participants
Selection of subjects from a panel was made by an ophthal-
mologist investigator by means of a prestudy questionnaire 
and medical examination based on the inclusion and exclu-
sion criteria.
inclusion criteria
Healthy 18 to 70-year-old Caucasian men or women able and 
willing to give informed consent who identified themselves 
as having sensitive skin of the eye contour and eyelid and 
who were either contact lens users or had a personal or family 
history of atopy were eligible for inclusion.
Subjects with sensitive skin were those who reported 
abnormal and repeated reactions of the skin (tightness, prick-
ling, itching, redness) to face care products, hygiene products 
(including soap), the environment during a major part of the 
year, or other factors such as water, clothes, or shaving.
Sensitive eyes were defined to include frequent prickling 
of the eyes, episodic watering, or becoming red in contact 
with environmental factors. Reaction to at least one of wind, 
cold, sun, and allergens and/or at least three of light; water 
(shower, swimming pool); ocular pain when watching televi-
sion, reading, driving, or using a computer; use of cosmetics; 
or exposure to pollution. Fear of exposure to sunlight and 
constant wearing of sunglasses was not, in itself, an inclu-
sion criterion.
A personal history of atopy was defined as a history of 
constitutional eczema, mostly appearing during childhood 
and mostly located in the skin folds; recurrent periodic 
asthma in childhood or preteenage years (no asthma crisis 
should have occurred during the last 6 months); recurrent 
periodic (chronic) conjunctivitis; or pneumallergen-related 
allergic rhinitis. A family history of atopy was defined as 
at least two parents or siblings with a history of atopic der-
matitis, allergic asthma in the first half of life, hay fever, or 
dermo-respiratory syndrome.
Exclusion criteria
The health status of subjects was verified by the inves-
tigator by means of a detailed history, with particular 
attention to gynecologic, medical, surgical, and   cutaneous 
  conditions as well as vaccination status and smoking habits. 
The following categories of subjects were excluded from 
the study:
•	 Pregnant or breastfeeding mothers, or subjects not using 
a medically acceptable contraceptive method; subjects 
having undergone organ excision, organ transplant, or 
skull concussion with extended loss of consciousness; 
and subjects with a known medical history, disorder, 
or disease and/or any complicating factor or structural 
abnormality judged by the investigator to be incompatible 
with the study;
•  Subjects
-	 who had undergone ocular surgery or on long-
term treatment, in particular with antihistaminics, 
  steroids, beta blockers (including eye lotion), and/or 
desensitization
-	 with a history of drug intolerance or allergy to prod-
ucts for professional use
-	 with a skin disease
-	 with a disease of the immune system or on immuno-
suppressive treatment or having had an asthma crisis 
during the last 6 months
-	 who smoke more than the equivalent of ten cigarettes 
a day or consume more than the equivalent of two 
glasses of wine per day, or those exhibiting drug abuse 
and/or excessive use of medications
-	 currently involved in another biomedical research 
project
-		 who had an asthma crisis during the last six months 
-	 with macroscopic traces of irritation or any other 
abnormality on the areas of product application that 
could interfere in the analysis of the results or having 
taken, in the past 3 months, medical treatment that is, in 
the ophthalmologist investigator’s judgment, inconsis-
tent with the participation in the study and thus makes 
him/her ineligible, in particular for anti-inflammatories 
applied on the test area within the 2 weeks before the 
beginning of the study and corticoids during the month 
before the beginning of the study
-	 currently receiving anti-allergy injections, with a final 
injection within the last 8 days (except lag effect corticoid 
injection for which the last one must be 6 months before), 
or expecting to begin injections during the study
-	 with a febrile illness
-	 who had been vaccinated in the month preceding the 
start of the study or expecting to be vaccinated during 
the study
-	 who had modified their cosmetic habits in face clean-
ing during the last 2 weeks or who had applied a 
cosmetic product on the areas concerned by the study 
on the inclusion day of the study
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-	 having skin recently exposed to sunlight (natural or 
artificial) or having had heliotherapy in the last 2 
weeks
-	 who had undergone surgery on the concerned areas 
(face, eye contours) or chemical or physical treatment 
to the face (eg, peeling, injections).
Other medication during the study or in the week before 
(excepting paracetamol and oral contraceptives) was not 
permitted and constituted grounds for exclusion. Protocol 
violations or emergence of exclusion criteria were also 
grounds for withdrawal from the study.
Product application
Subjects were instructed on the appropriate method of 
application of the product in which a single pump of product 
(representing a mean volume of 0.46 mL) was to be applied 
on nonsterile, nonwoven compresses given to the subject for 
3 weeks, by gentle massage to the eyelids, eyelashes, and 
around the orbit. Remaining product was to be removed by 
compress. Subjects were advised not to apply the product 
into the eye.
Outcome measures
Ophthalmologic examination
On the first and last day of the study, subjects underwent a 
structured ophthalmologic examination in which the state of 
the eyelids, palpebral margin and eyelashes, tarsal or bulbar 
conjunctiva, cornea, anterior chamber, direct and consensual 
photomotor reflexes, and fluorescein tear breakup time were 
rated on predefined ordinal scales. In addition, measurement 
of visual acuity was performed.
The right and left eyes of each subject were examined by 
the ophthalmologist investigator to evaluate the condition of 
the eyelids on macroscopic examination quantified accord-
ing to a 0–4 scale (0 = normal; 1 = slightly red skin; 2 = red 
and edematous skin; 3 = lid eczema; 4 =   desquamation). 
  Palpebral margin and eyelashes were examined using a slit 
lamp (Nikon Corporation, Shinjuku, Japan,  Zoom photo, Slit 
lamp FS 3) and rated according to a 0–3 scale (0 = normal; 
1 = local redness on the palpebral margin only; 2 = secre-
tions and crusts on the eyelashes; 3 = falling eyelashes, 
considerable blepharitis). The state of the tarsal or bulbar 
conjunctiva was evaluated using a slit lamp according to 
a 0–4 scale (0 = normal; 1 = slight redness [vasodilatation 
visible only with the slit lamp]; 2 = clearly visible redness 
[clear vasodilatation visible macroscopically]; 3 = some 
small follicles and   papillae; 4 = numerous follicles and 
large papillae). Corneal condition was evaluated by slit lamp   
according to a 0–4 scale (0 = normal; 1 = slight   localized 
cellular alterations; 2 = clear and spread cellular alterations; 
3 = superficial punctuate keratitis on the whole cornea; 
4 = corneal ulcer and edema). The anterior chamber was 
evaluated according to a 0–3 scale (0 = normal; 1 = tyndall; 
2 = full-blown iritis or descemetitis; 3 = hypopion). Direct and 
consensual photomotor reflexes were evaluated by ophthal-
moscope lamp according to a 0–2 scale (0 = normal; 1 = slow; 
2 = nil). Fluorescein tear film breakup time value was scored in 
seconds as the average of the two   measurements, with a third 
measurement taken in case of discrepancy .2 seconds.
The nature and sensitivity of the subject’s facial and eye 
contour/eyelid skin was also evaluated at the first visit using 
the following categorization: normal, mixed oily, oily, mixed 
dry, dry, and very dry.
The subjects were questioned regarding the acceptability 
and efficiency of the product by means of a questionnaire 
designed for “in-use test under ophthalmologic control” and 
validated by the research organization responsible for the 
study. The questionnaire was applied by the investigating 
ophthalmologist.
Functional signs
On the last day of the study the ophthalmologist   investigator 
assessed the degree of discomfort felt by the subject in terms 
of symptoms of palpebral pruritus, ocular prickling, transi-
tory heat, ocular pain, eye watering, discomfort to light, 
transitory mist, palpebral redness, palpebral desquamation, 
palpebral swelling, eyelash involvement, secretions, and 
ocular redness on a 4-point ordinal scale (0 = no functional 
signs; 1 = very slight discomfort; 2 = notable discomfort; 
3 = symptoms sufficiently serious to limit the subject’s 
daily activities).
Effect on contact lenses
On the last day of the study, examination was undertaken of 
contact lenses according to deposits, coloration, opacifica-
tion, variation in mobility, and changes in the suppleness of 
lenses on a 4-point ordinal scale (0 = absence of reaction; 
1 = start of reaction; 2 = moderate reaction; 3 = severe 
reaction).
Acceptability and efficiency questionnaire
Acceptability and efficiency (as a “cleaning product for 
eyelids and eyelashes”) of the product was assessed by a self-
administered questionnaire (on a 5-point ordinal scale: nil, 
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poor, fairly good, good, very good) and an overall appraisal 
given verbally to the investigator.
Adverse events
Adverse events, if any, were reported by the subjects. 
In addition, the examining ophthalmologist identified 
changes in the medical status of the subjects between the 
first and final visit.
Subjects were withdrawn from the study upon emer-
gence of adverse events considered to be linked to the study 
product.
Results
Subject disposition
Fifty-six subjects were recruited, of whom 37 attended the 
clinic for the first visit. Thirty-three were then entered into 
the study. All subjects returned at the final visit and were 
evaluable for acceptability and safety.
Subject characteristics
The subjects were predominantly female (85%) with a mean 
age of 47.8 years (range 20–69 years). The nature of the 
subject’s facial skin was evaluated as normal (0%), mixed 
oily (30%), oily (0%), mixed dry (45%), dry (21%), and very 
dry (3%). All subjects were determined to have sensitive 
facial skin. The majority (64%) of subjects had dry skin of 
the eye contour and eyelid, with 33% and 3% having dry or 
very dry skin of the eye contour and eyelid, respectively. 
Again, all subjects had sensitivity of the skin of the eye 
contour and eyelid.
Of the subjects, 76% had sensitive eyes, 61% were 
contact lens wearers, and 39% had a personal or family 
history of atopy. A total of 36% were habitual users of the 
products similar to the investigational product, with 21% 
being regular users.
Ophthalmologist assessment
There were minor changes in the lachrymal film breakup 
time and visual acuity between the first and last visits, but 
neither achieved statistical or clinical significance (Figure 1). 
The visual acuity measurements obtained before and after 
the 3 weeks of application evolved within clinically accept-
able limits.
Safety and tolerability
Of the subjects, 85% reported no ocular or periocular signs 
or symptoms. Of the five subjects who reported clinical 
signs and symptoms, there were four reports of prickling, 
two reports of eye watering, and one each of palpebral 
swelling and tightness. Four reports of symptoms were 
attributed to a single subject. None of the adverse events 
was linked to the investigational product, and none led to 
withdrawal.
Acceptability and efficiency
Among the seven subjects who were habitual users of similar 
products, six assessed the investigational product as being as 
well tolerated as their usual product. The remaining subject 
reported their usual product as being better tolerated.
Following questioning by the investigating ophthalmolo-
gist, 85% of subjects rated the acceptability and 73% rated the 
efficiency of the product as good to very good (Figure 2).
Appraisal by the subject
The questionnaire responses are shown in Figure 3.
Of the subjects, 85% considered that “the product is 
ideally suitable for the cleansing of the eyelids, the mucus, 
and the squama that ‘clutter’ the eyelash roots.”
Moreover, the product was also appreciated for:
•	 its cosmetic qualities (“good enough”, consistency 
(85%), “good enough texture” (88%), “easy application” 
(94%), “does not leave the skin oily” (94%)/“sticky” 
(91%), “does not leave any traces” (94%)
Right eye Left eye
P = 0.628
P = 0.448
2
0
4
6
8
10
Start of study
End of study (3 weeks)
12
Figure 1 Lachrymal film breakup time before and after 3 weeks of Blephagel use (mean 
of three measures in 13 subjects). Lachrymal film measured by breakup time scored in 
seconds. The breakup time value was scored as the average of the two measurements, 
with the third measurement taken in case of discrepancy .2 seconds.
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very good by a large majority of the subjects. Ophthalmologic 
examination revealed no concerns, and the number of subjects 
reporting ophthalmologic signs was very low. There were no 
reports of adverse events linked to Blephagel.
The safety and tolerability of Blephagel have been 
demonstrated in in vitro and in vivo studies. Blephagel has 
been evaluated in the standard battery of tests for cosmetic 
products intended to be used around the eyes and has been 
shown to be safe and nonirritant. Although not intended 
for application in the eye, Blephagel has been tested in the 
isolated bovine cornea opacity and permeability test16 for 
ocular irritation and was rated in the lowest possible category 
for ocular irritation (manufacturer data on file). The bovine 
cornea opacity and permeability test is a standard in vitro 
technique in which the penetration of a fluorescein dye into 
bovine corneas in vitro is assessed. In an in vivo skin toler-
ability test involving 48 hours of continuous exposure to the 
skin on the back of ten human subjects, no signs of erythema, 
edema, papulae, vesicles, bulbae, or pustules were observed, 
nor evidence of dryness, desquamation, detergent effect, or 
reflectivity. The primary cutaneous irritation index calculated 
in this study was 0 (manufacturer data on file).
A further study, the so-called final clinical safety test, 
was carried out to confirm the good cutaneous compatibility 
and the absence of delayed cutaneous sensitizing potential in 
healthy adult subjects. Using the method of Marzulli and Mai-
bach,17 with single and repeated epicutaneous applications of 
the investigational product to elicit delayed reaction, the final 
clinical safety test similarly revealed no primary or cumula-
tive irritation reactions, nor any cutaneous sensitization to 
Blephagel, among 107 exposed subjects (manufacturer data 
on file). Further controlled clinical studies in larger groups 
of patients would be welcome to confirm these results.
Despite widespread acceptance of eyelid hygiene as 
the most effective means of treatment and prevention of 
blepharitis, formal studies are scarce, though studies have 
indicated that such regimes improve the quality and thickness 
of meibomian gland secretions in subjects with disorder of 
the meibomian glands.18,19
The present study shows Blephagel to be well tolerated 
and accepted in a subject population who could be considered 
to be particularly sensitive to the application of such products. 
Blephagel may be a useful and convenient addition to the 
daily eyelid hygiene regime of blepharitis sufferers.
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Figure 2 Appraisal of efficiency and acceptability by subjects in the presence of the 
investigating ophthalmologist. Acceptability and efficiency (as a “cleaning product 
for  eyelids  and  eyelashes”)  of  the  product  was  assessed  by  a  self-administered 
questionnaire (on a 5-point ordinal scale: nil, poor, fairly good, good, very good).
•	 the felt sensations (“gives a pleasant sensation of fresh-
ness” (85%), “softens” (79%), “soothes the eyelids” 
(79%), “leaves the eyelids comfortable” (88%)
•	 its acceptability (“suitable for the subjects skin type” 
(97%), “for sensitive skins” (97%)/“eyelids” (94%).
Discussion
Hygiene of the eyelids is crucial to the prevention of   blepharitis. 
The present study has further indicated that Blephagel is well 
accepted and appreciated by subjects with risk factors for 
susceptibility (the majority of whom had multiple risk factors) 
themselves. Acceptability and efficacy were rated as good or 
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